In March 2017, the European Patent Office (EPO) announced its intention to allow claims to Max-Planck Institute in Berlin, University of California, and University of Vienna,[211][212] and in August 2017, the EPO announced its intention to allow CRISPR claims in a patent application that MilliporeSigma had filed.[211] As of August 2017 the patent situation in Europe was complex, with MilliporeSigma, ToolGen, Vilnius University, and Harvard contending for claims, along with University of California and Broad.[213]